AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17971530 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 150
Study 15126741 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser myringotomy
Number of subjects: 208
Study 15126741 — intervention group
Group type: COMPARATOR
Intervention: Ventilation tubes
Number of subjects: 208
Study 11239907 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 36
Study 11239907 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 36
Study 11239907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9478315 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (341 mg once a week)
Number of subjects: 80
Study 9478315 — intervention group
Group type: COMPARATOR
Intervention: Natural Progesterone (50 mg/day)
Number of subjects: 80
Study 8176180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin eyedrops
Number of subjects: 95
Study 8176180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% flurbiprofen eyedrops
Number of subjects: 95
Study 8176180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 3295212 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 199
Study 3295212 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine gum
Number of subjects: 199
Study 30685751 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-peer tutors (newly graduated doctors)
Number of subjects: 241
Study 30685751 — intervention group
Group type: COMPARATOR
Intervention: Staff tutors
Number of subjects: 241
Study 29665062 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% JTE-052 ointment
Number of subjects: 0
Study 29665062 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% JTE-052 ointment
Number of subjects: 0
Study 29665062 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 0
Study 29665062 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 0
Study 29665062 — intervention group
Group type: COMPARATOR
Intervention: Non-application
Number of subjects: 0
Study 26854386 — intervention group
Group type: EXPERIMENTAL
Intervention: epoc® blood analysis system
Number of subjects: 40
Study 24767638 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 1 mg/mL ropivacaine and 2 μg/mL fentanyl (Group A)
Number of subjects: 480
Study 24767638 — intervention group
Group type: EXPERIMENTAL
Intervention: PCEA with 0.8 mg/mL bupivacaine (Group B)
Number of subjects: 480
Study 24767638 — intervention group
Group type: EXPERIMENTAL
Intervention: CEI with 1 mg/mL ropivacaine (Group C)
Number of subjects: 480
Study 24767638 — intervention group
Group type: EXPERIMENTAL
Intervention: CEI with 0.8 mg/mL bupivacaine (Group D)
Number of subjects: 480
Study 22364262 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day) with ursodeoxycholic acid (UDCA) (600 mg/day)
Number of subjects: 85
Study 22364262 — intervention group
Group type: COMPARATOR
Intervention: UDCA alone
Number of subjects: 85
Study 20698351 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical difluoromethylornithine (DFMO)
Number of subjects: 102
Study 20698351 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Triamcinolone
Number of subjects: 102
Study 20698351 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical difluoromethylornithine (DFMO) + Triamcinolone
Number of subjects: 102
Study 20698351 — intervention group
Group type: COMPARATOR
Intervention: Eucerin + Eucerin (double placebo)
Number of subjects: 102
Study 17442512 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangxin capsule
Number of subjects: 56
Study 16100159 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-PGE1 (10 microg bid for 14 days)
Number of subjects: 49
Study 16100159 — intervention group
Group type: EXPERIMENTAL
Intervention: lipo-PGE1
Number of subjects: 49
Study 11829697 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/d of conjugated equine estrogen plus 2.5 mg/d of medroxyprogesterone acetate (n = 1380)
Number of subjects: 2763
Study 11829697 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 1383)
Number of subjects: 2763
Study 11829697 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (hormone therapy and placebo)
Number of subjects: 2763
Study 10510146 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐NMMA (4 mg kg‐1 bolus, with 4 mg kg‐1 infusion)
Number of subjects: 10
Study 10510146 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (0.5 microg kg‐1 min‐1)
Number of subjects: 10
Study 10510146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8731849 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg vitamin C twice a day for 3 months
Number of subjects: 316
Study 8731849 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets for 3 months
Number of subjects: 316
Study 16296711 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg once daily)
Number of subjects: 80
Study 16296711 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (60-120 mg three times daily)
Number of subjects: 80
Study 6111965 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbonated beverage with syrup of ipecac
Number of subjects: 24
Study 6111965 — intervention group
Group type: COMPARATOR
Intervention: Water with syrup of ipecac
Number of subjects: 24
Study 31888766 — intervention group
Group type: EXPERIMENTAL
Intervention: Maize flour enriched through agro-biofortification with Se
Number of subjects: 360
Study 31888766 — intervention group
Group type: COMPARATOR
Intervention: Control flour not enriched with Se
Number of subjects: 360
Study 28364426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) alone
Number of subjects: 160
Study 28364426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) combined with zolpidem as needed
Number of subjects: 160
Study 28364426 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) with zolpidem tapered
Number of subjects: 160
Study 28364426 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT) with continued zolpidem as needed
Number of subjects: 160
Study 28364426 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Cognitive-Behavioral Therapy (CBT)
Number of subjects: 160
Study 25594222 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour oral glucose tolerance test (OGTT) values (fasting, 1-hour, 2-hour, and 3-hour)
Number of subjects: 1360
Study 25594222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting glucose between 85 and 94 mg/dL
Number of subjects: 1360
Study 25594222 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting OGTT < 95 mg/dL
Number of subjects: 1360
Study 25594222 — intervention group
Group type: EXPERIMENTAL
Intervention: Other OGTT values (1-hour, 2-hour, 3-hour)
Number of subjects: 1360
Study 24093709 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Stoppa approach
Number of subjects: 60
Study 24093709 — intervention group
Group type: COMPARATOR
Intervention: Ilioinguinal approach
Number of subjects: 60
Study 21872979 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐Blocker therapy
Number of subjects: 1747
Study 21872979 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐Blocker therapy in patients with IHD
Number of subjects: 1747
Study 21872979 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐Blocker therapy in patients without IHD
Number of subjects: 1747
Study 19657924 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency format
Number of subjects: 0
Study 19657924 — intervention group
Group type: COMPARATOR
Intervention: 1-in-N format
Number of subjects: 0
Study 19657924 — intervention group
Group type: COMPARATOR
Intervention: Visual format
Number of subjects: 0
Study 19657924 — intervention group
Group type: EXPERIMENTAL
Intervention: High numeracy levels
Number of subjects: 0
Study 19657924 — intervention group
Group type: EXPERIMENTAL
Intervention: Low numeracy levels with frequency format
Number of subjects: 0
Study 18068613 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 77
Study 18068613 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional drug)
Number of subjects: 77
Study 15168319 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin treatment
Number of subjects: 0
Study 15168319 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study 11440064 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized-patient (SP) cases on cancer screening and literacy, incorporated into the curriculum for second-year students.
Number of subjects: 0
Study 11440064 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning (PBL) case on breast cancer screening and literacy.
Number of subjects: 0
Study 11440064 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical practice examination on colorectal cancer screening and literacy.
Number of subjects: 0
Study 9649984 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 5 mL saline (Group B)
Number of subjects: 60
Study 9649984 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 10 mL saline (Group C)
Number of subjects: 60
Study 9649984 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 15 mL saline (Group D)
Number of subjects: 60
Study 9649984 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural midazolam 0.05 mg kg‐1 in 3 mL saline (Group A)
Number of subjects: 60
Study 7662126 — intervention group
Group type: EXPERIMENTAL
Intervention: freeze-dried plasma containing a high titre of anti-lipopolysaccharide (anti-LPS) IgG
Number of subjects: 60
Study 7662126 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 2225184 — intervention group
Group type: EXPERIMENTAL
Intervention: sulpiride
Number of subjects: 40
Study 2225184 — intervention group
Group type: COMPARATOR
Intervention: perphenazine
Number of subjects: 40
Study 282079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone, frusemide, or mefruside for 4 weeks (group A)
Number of subjects: 29
Study 282079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone for 6 weeks (group B)
Number of subjects: 29
Study 282079 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone, frusemide, or mefruside
Number of subjects: 29
Study 31752521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab monthly (225 mg at baseline, weeks 4 and 8)
Number of subjects: 865
Study 31752521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab quarterly (675 mg at baseline, placebo at weeks 4 and 8)
Number of subjects: 865
Study 31752521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fremanezumab (both monthly and quarterly)
Number of subjects: 865
Study 31752521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 865
Study 30914002 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated specialty care
Number of subjects: 75
Study 27552353 — intervention group
Group type: EXPERIMENTAL
Intervention: Occluded tracheostomy tubes
Number of subjects: 20
Study 27552353 — intervention group
Group type: COMPARATOR
Intervention: Open tracheostomy tubes
Number of subjects: 20
Study 25591873 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazoxide (7 mg/kg)
Number of subjects: 12
Study 25591873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22739821 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic breathing and muscle-strengthening and flexibility exercises for 8 weeks
Number of subjects: 15
Study 22739821 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinematics motion analysis (exploratory)
Number of subjects: 15
Study 20729034 — intervention group
Group type: EXPERIMENTAL
Intervention: Air inflated cuffs
Number of subjects: 90
Study 20729034 — intervention group
Group type: EXPERIMENTAL
Intervention: O₂‐N₂O mix inflated cuffs
Number of subjects: 90
Study 20729034 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline solution inflated cuffs
Number of subjects: 90
Study 18191817 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 8
Study 18191817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 15671432 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant (2 doses of 80 mL/m2)
Number of subjects: 153
Study 15671432 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equal volume of air)
Number of subjects: 153
Study 15671432 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 153
Study 15671432 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant and Placebo
Number of subjects: 153
Study 12972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpretive group therapy
Number of subjects: 61
Study 12972855 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive group therapy
Number of subjects: 61
Study 12972855 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (interpretive and supportive)
Number of subjects: 61
Study 10228057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine-containing regimen
Number of subjects: 20
Study 10228057 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir, saquinavir, abacavir, and nevirapine
Number of subjects: 20
Study 9033201 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler vasomotor reflex testing
Number of subjects: 172
Study 9033201 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study 2064719 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol challenge
Number of subjects: 24
Study 2064719 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 24
Study 6388832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent high-dose melphalan/prednisone (MP) treatment
Number of subjects: 130
Study 6388832 — intervention group
Group type: COMPARATOR
Intervention: Human leukocyte interferon (IFN) administration
Number of subjects: 130
Study 31707816 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Temperature Management (TTM)
Number of subjects: 0
Study 31707816 — intervention group
Group type: COMPARATOR
Intervention: Mild Therapeutic Hypothermia (THT)
Number of subjects: 0
Study 29682995 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of isosorbide dinitrate spray and chitosan gel
Number of subjects: 68
Study 29682995 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate spray
Number of subjects: 68
Study 29682995 — intervention group
Group type: EXPERIMENTAL
Intervention: Chitosan gel
Number of subjects: 68
Study 29682995 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 26972635 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional resistance training (TD)
Number of subjects: 25
Study 26972635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyramidal resistance training (PR)
Number of subjects: 25
Study 24470342 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times daily)
Number of subjects: 700
Study 24470342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 23110494 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg) biannually
Number of subjects: 4500
Study 23110494 — intervention group
Group type: COMPARATOR
Intervention: Snail control with niclosamide
Number of subjects: 4500
Study 23110494 — intervention group
Group type: COMPARATOR
Intervention: Behaviour change interventions
Number of subjects: 4500
Study 23110494 — intervention group
Group type: COMPARATOR
Intervention: Health system, water and sanitation infrastructure improvements
Number of subjects: 4500
Study 21050332 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reminiscence protocol offered twice weekly for 6 weeks
Number of subjects: 0
Study 21050332 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured reminiscence protocol (duration longer than 3 weeks)
Number of subjects: 0
Study 17379055 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of tacrolimus (1 mg capsules, twice daily for a total daily dose of 4 mg)
Number of subjects: 29
Study 17379055 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of tacrolimus (1 mg capsules, twice daily for a total daily dose of 4 mg)
Number of subjects: 29
Study 17219281 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy in women
Number of subjects: 132
Study 17219281 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy in men
Number of subjects: 132
Study 17219281 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy in men
Number of subjects: 132
Study 15682350 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV 250 mg to 1250 mg twice daily for 11 days followed by RTV 100 mg for 21 days
Number of subjects: 95
Study 15682350 — intervention group
Group type: EXPERIMENTAL
Intervention: TPV 500 mg and 750 mg with RTV 100 mg or 200 mg
Number of subjects: 95
Study 15682350 — intervention group
Group type: EXPERIMENTAL
Intervention: All TPV/r combinations
Number of subjects: 95
Study 15682350 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events
Number of subjects: 95
Study 10623704 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) with l‐OHP (125 mg/m(2), as a 6‐hour infusion)
Number of subjects: 200
Study 10623704 — intervention group
Group type: COMPARATOR
Intervention: 5‐day course of chronomodulated 5‐FU (700 mg/m(2)/d) and LV (300 mg/m(2)/d) without l‐OHP
Number of subjects: 200
Study 10623704 — intervention group
Group type: COMPARATOR
Intervention: 5‐day course of chronomodulated 5‐FU and LV
Number of subjects: 200
Study 10623704 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐day course of chronomodulated 5‐FU and LV with l‐OHP
Number of subjects: 200
Study 9361574 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (training program)
Number of subjects: 31
Study 9361574 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition (control)
Number of subjects: 31
Study 1337070 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 250 mg bd for 2 days followed by 250 mg od for 8 days
Number of subjects: 64
Study 1337070 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline, 100 mg bd for 14 days
Number of subjects: 64
Study 1337070 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin, 1 million IU tds for 14 days
Number of subjects: 64
Study 1337070 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 64
Study 3986069 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine (group II)
Number of subjects: 17
Study 3986069 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural morphine and bupivacaine (group III)
Number of subjects: 17
Study 3986069 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine alone (group I)
Number of subjects: 17
Study 30665814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with sequential stereotactic body radiotherapy (SBRT)
Number of subjects: 18
Study 30665814 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with concomitant stereotactic body radiotherapy (SBRT)
Number of subjects: 18
Study 29061617 — intervention group
Group type: EXPERIMENTAL
Intervention: HEART score calculation by physicians in daily practice
Number of subjects: 1752
Study 29061617 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorrect HEART score
Number of subjects: 1752
Study 26186702 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler monitor (ODM, CardioQ‐ODM)
Number of subjects: 21
Study 26186702 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse power wave analysis (PPA, LiDCOrapid)
Number of subjects: 21
Study 26186702 — intervention group
Group type: EXPERIMENTAL
Intervention: PPA group
Number of subjects: 21
Study 23872048 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated motor imagery practice
Number of subjects: 23
Study 23872048 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (executed exercises to improve upper extremity function)
Number of subjects: 23
Study 23872048 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 23
Study 21818648 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion of family health history with a physician
Number of subjects: 632
Study 21818648 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of responsibility for initiating discussions
Number of subjects: 632
Study 21818648 — intervention group
Group type: EXPERIMENTAL
Intervention: Having a discussion with a physician
Number of subjects: 632
Study 19553404 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg infused over 1 hour
Number of subjects: 0
Study 19553404 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg infused over 4 hours
Number of subjects: 0
Study 19553404 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 1000 mg infused over 4 hours
Number of subjects: 0
Study 19553404 — intervention group
Group type: EXPERIMENTAL
Intervention: All regimens of doripenem
Number of subjects: 0
Study 19553404 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group in Study 1)
Number of subjects: 0
Study 18225515 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using Photosens (aluminum phthalocyanine) intravenously injected at a dose of 0.05 mg/kg, with laser irradiation at 675 nm and exposure light dose of 120 J/cm2, total light dose not greater than 500 J/cm2.
Number of subjects: 32
Study 18225515 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (control group).
Number of subjects: 32
Study 15066462 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg/d orally)
Number of subjects: 41
Study 15066462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 11774805 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention including patient education, self-monitoring of blood glucose, and determination of HbA1c levels.
Number of subjects: 416
Study 11774805 — intervention group
Group type: COMPARATOR
Intervention: Customary care (control group).
Number of subjects: 416